4 stories mentioning TWSTUpdated just now
Every FINWIRES story that references TWST, newest first.
Twist Bioscience (TWST) has an average rating of buy and mean price target of $87.56, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $95.66, Change: $+4.11, Percent Change: +4.49%
Emily M. Leproust, Director, Chief Executive Officer, on June 25, 2026, sold 18,880 shares in Twist Bioscience (TWST) for $1,793,600. Following the Form 4 filing with the SEC, Leproust has control over a total of 824,039 common shares of the company, with 824,039 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1581280/000121465926007800/xslF345X05/marketforms-73475.xml
Twist Bioscience (TWST) has an average rating of buy and mean price target of $73.12, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Twist Bioscience (TWST) has an average rating of buy and mean price target of $65.67, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
